VolitionRx
Volition Eyes East Asia Expansion With Nucleosome-Based Blood Test for Lung Cancer Screening
Premium
The firm hopes to include its lung cancer assay in Taiwan's national cancer screening program while developing sepsis and ovarian cancer assays.
In Brief This Week: Quest Diagnostics; Aspira Women's Health; Trinity Biotech; VolitionRx; DNANudge
News items for the week of Aug. 12, 2024.
VolitionRx to Raise up to $21.5M in Registered Direct Offering
The firm expects to bring in $7 million upfront and up to another $14.5 million through milestone-linked warrants.
In Brief This Week: Thermo Fisher Scientific; VolitionRx; Aspira Women's Health; Mainz Biomed; More
News items for the week of July 1 and July 8, 2024.
VolitionRx Gets €5M Financing From Wallonie Entreprendre
The Nevada-based epigenetics firm will receive half the money through an unsecured loan and half through the sale of restricted common stock.
Jun 1, 2023
VolitionRx Prices $16.5M Public Offering
Feb 17, 2023
VolitionRx Prices $7.5M Public Offering
Jul 29, 2022
VolitionRx Prices $6M Public Offering
May 31, 2022
VolitionRx Gets CE Mark for NETosis Test
Feb 10, 2021
VolitionRx Prices $20M Public Offering
May 20, 2020